Increased incidence of vulvovaginal candidiasis caused by Candida glabrata in Jordan

Japanese Journal of Infectious Diseases

Volumn 54, Issue 3, 2001, Pages 103-107

  Abu Elteen, K H ^a  

^a Hashemite University   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ADULT; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; DRUG SENSITIVITY; FEMALE; GYNECOLOGY; HUMAN; INCIDENCE; JORDAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MYCOLOGY; OBSTETRICS; OPPORTUNISTIC INFECTION; OUTPATIENT DEPARTMENT; STATISTICAL ANALYSIS; SYMPTOM; TIME; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA SMEAR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CANDIDA; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; INCIDENCE; JORDAN; LEUKORRHEA; MIDDLE AGED; SENTINEL SURVEILLANCE; VAGINAL DISCHARGE;

EID: 0034811629     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Pathogenesis and treatment of recurrent vulvovaginal candidiasis
2. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis
3. Treatment of recurrent vulvovaginal candidiasis
4. Limitations of antifungal agents in the treatment of Candida vaginitis: Future challenges
5. Candidiasis of the genitalia
6. Dynamics of candida isolations from humans from 1992-1995 in Greifswald, Germany
7. Nosocomial candidiasis: Emerging species, reservoirs, and modes
8. Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans
9. Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital
10. New and emerging yeast species
11. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
12. Importance of Candida species other than C. albicans as pathogens in oncology patients
13. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
14. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia
15. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
16. The epidemiology of hematogenous candidiasis caused by different Candida species
17. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period
18. Resistance of Candida species to fluconazole
19. Vulvovaginal candidiasis: Topical versus oral therapy
20. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species
21. Vulvovaginal candidiasis: Epidemiologic, diagnosis, and the therapeutic considerations
22. Weekly fluconazole for the treatment of mucosal candidiasis in women with HIV infection. A randomized, double blind, placebo controlled trial
23. Chronic urinary tract infection due to Candida utilis
24. Microbiological characteristics of yeasts isolated from urinary tracts of intensive care unit patients undergoing urinary catheterization
25. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly
26. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species
27. Candida, Cryptococcus, and other yeasts of medical importance
28. Infection control: Opportunistic fungal infections-the increasing importance of Candida species
29. Prevalence and susceptibility of vaginal yeast isolates in Jordan
30. Characterization of yeasts implicated in vulvovaginal candidiasis in Irish women
31. Use of CHROMagar Candida for genital specimens in the diagnostic laboratory
32. An evaluation of the cost-effectiveness of using CHROMagar for yeast identification in a routine microbiology laboratory
33. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata
34. Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: The emergence of Candida glabrata
35. Candida krusei fungemia
36. Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation
37. Evaluation of Etest for direct antifungal susceptibility testing of yeasts in positive blood cultures
38. Genital yeasts in female patients attending a VD clinic
39. Chronic vulvovaginal candidiasis: Characteristics of women with Candida albicans, Candida glabrata, and no Candida